Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells

International Journal of Oncology

Volumn 40, Issue 5, 2012, Pages 1705-1713

  Ong, Pei Shi ^a   Wang, Xin Qiao ^a   Lin, Hai Shu ^a   Chan, Sui Yung ^a   Ho, Paul C ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Apoptosis; Drug synergism; Histone deacetylase inhibitors; Platinum

Indexed keywords

CISPLATIN; VORINOSTAT;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL DEATH; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; FIBROBLASTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INHIBITORY CONCENTRATION 50; OVARIAN NEOPLASMS;

EID: 84860266447     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1354     Document Type: Article

References (51)

1. Markman M: Pharmaceutical management of ovarian cancer: current status. Drugs 68: 771-789, 2008.
2. Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784, 2006. (Pubitemid 44348499)
3. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK and Benz CC: Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45: 495-528, 2005. (Pubitemid 40261815)
4. Monneret C: Histone deacetylase inhibitors. Eur J Med Chem 40: 1-13, 2005.
5. Minucci S and Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51, 2006. (Pubitemid 43054973)
6. Ogryzko VV, Hirai TH, Russanova VR, Barbi DA and Howard BH: Human fibroblasts commitment to a senescence-like state in response to histone deacetylase inhibitors is cell cycle dependent. Mol Cell Biol 16: 5210-5218, 1996. (Pubitemid 26272174)
7. Chen Z, Clark S, Birkeland M, Sung CM, Lago A, Liu R, Kirkpatrick R, Johanson K, Winkler JD and Hu E: Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45)α and β messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Lett 188: 127-140, 2002. (Pubitemid 35299421)
8. Marks PA, Richon VM and Rifkind RA: Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210-1216, 2000. (Pubitemid 30627729)
9. Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM, Garcia-Vargas J, Sanz-Rodriguez C and Rizvi S: Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2: 31-42, 2009.
10. Takai N, Kawamata N, Gui D, Said JW, Miyakawa I and Koeffler HP: Human ovarian carcinoma cells: histone-deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 101: 2760-2770, 2004. (Pubitemid 39603184)
11. Takai N, Ueda M, Nishida M, Nasu K, Matsuda K, Kusumoto M and Narahara H: CBHA is a family of hybrid polar compounds that inhibit histone deacetylase, and induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Oncology 70: 97-105, 2006. (Pubitemid 43760335)
12. Takai N, Ueda T, Nishida M, Nasu K and Narahara H: A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells. J Mol Med 17: 323-329, 2006.
13. Takai N, Ueda T, Nishida M, Nasu K and Narahara H: M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells. Gynecol Oncol 101: 108-113, 2006.
14. Ueda T, Takai N, Nishida M, Nasu K and Narahara H: Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells. Int J Mol Med 19: 301-308, 2007.
15. Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS and Jeffers M: Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 5: 2086-2095, 2006. (Pubitemid 44336581)
16. Strait KA, Warnick CT, Ford CD, Dabbas B, Hammond EH and Ilstrup SJ: Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad. Mol Cancer Ther 4: 603-611, 2005. (Pubitemid 40601842)
17. Chao KC, Chang CC, Yen MS and Wang PH: Anti-tumor activity of histone deacetylase inhibitors and the effect on ATP-binding cassette in ovarian carcinoma cells. Eur J Gynaecol Oncol 31: 402-410, 2010.
18. Marks PA: Discovery and development of SAHA as an anticancer agent. Oncogene 26: 1351-1356, 2007.
19. Grant S, Easley C and Kirkpatrick P: Vorinostat. Nat Rev Drug Discov 6: 21-22, 2007. (Pubitemid 46020282)
20. Taki N and Narahara H: Histone deacetylase inhibitor therapy in epithelial ovarian cancer. J Oncol 2010: 458431, 2010.
21. Mann BS, Johnson JR, Sridhara R, Abraham S, Booth BP, Verbois L, Morse DE, Jee JM, Pope S, Harapanhalli RS, Dagher R, Farrell A, Justice R and Pazdur R: Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 13: 2318-2322, 2007. (Pubitemid 46698579)
22. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM and Frankel SR: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109: 31-39, 2007. (Pubitemid 46053039)
23. Du YH and Ho PC: Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines. Cancer Chemother Pharmacol 47: 481-490, 2001.
24. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
25. Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681, 2006.
26. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P and Traganos F: Features of apoptotic cells measured by flow cytometry. Cytometry 13: 795-808, 1992.
27. Cooper AL, Greenberg VL, Lancaster PS, van Nagell JR Jr, Zimmer SG and Modesitt SC: In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecol Oncol 104: 596-601, 2007. (Pubitemid 46240243)
28. Rundall BK, Denlinger CE and Jones DR: Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer. Surgery 138: 360-367, 2005. (Pubitemid 41253822)
29. Sonnemann J, Gange J, Kumar KS, Muller C, Bader P and Beck JF: Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. Invest New Drugs 23: 99-109, 2005. (Pubitemid 40386226)
30. Denlinger CE, Rundall BK and Jones DR: Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg 128: 740-748, 2004. (Pubitemid 39388930)
31. Rundall BK, Denlinger CE and Jones DR: Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death. Surgery 136: 416-425, 2004. (Pubitemid 39037682)
32. Owonikoko TK, Ramalingam SS, Kanterewicz B, Baliu T, Belani CP and Hershberger PA: Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells. Int J Cancer 126: 743-755, 2010.
33. Lin CT, Lai HC, Lee HY, Lin WH, Chang CC, Chu TY, Lin YW, Lee KD and Yu MH: Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci 99: 1218-1226, 2008.
34. Camphausen K, Burgan W, Cerra M, Oswald KA, Trepel JB, Lee MJ and Tofilon PJ: Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 64: 316-321, 2004. (Pubitemid 38114113)
35. Candelaria M, Gallardo-Rincón D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O, González-Fierro A, Chávez-Blanco A, De la Cruz-Hernández E, Camargo MF, Trejo-Becerril C, Pérez- Cárdenas E, Pérez-Plasencia C, Taja-Chayeb L, Wegman-Ostrosky T, Revilla-Vazquez A and Dueñas-González A: A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 18: 1529-1538, 2007.
36. Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, Thomas S, Espinoza-Delgado I, Vokes EE, Gandara DR and Belani CP: Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 28: 56-62, 2010.
37. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM and Munster PN: Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 92: 223-237, 2004.
38. Sato T, Suzuki M, Sato Y, Echigo S and Rikiishi H: Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. Int J Oncol 28: 1233-1241, 2006.
39. WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97: 10014-10019, 2000.
40. Kelly WK and Marks PA: Drug insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2: 150-157, 2005. (Pubitemid 40823166)
41. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E and Bhalla K: Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280: 26729-26734, 2005. (Pubitemid 41040705)
42. Zhou Q, Chaerkady R, Shaw PG, Kensler TW, Pandey A and Davidson NE: Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. Proteomics 10: 1029-1039, 2010.
43. Chen CS, Weng SC, Tseng PH, Lin HP and Chen CS: Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 280: 38879-38887, 2005.
44. Xu W, Perez G, Ngo L, Gui C and Marks PA: Induction of polyploidy by histone deacetylase inhibitor: A pathway for antitumor effects. Cancer Res 65: 7832-7839, 2005. (Pubitemid 41297259)
45. Marks PA, Miller T and Richon VM: Histone deacetylases. Curr Opin Pharmacol 3: 344-351, 2003. (Pubitemid 36908937)
46. Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA, Marks PA, Richon VM and Butler LM: Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther 6: 51-60, 2007. (Pubitemid 46209918)
47. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S and Pelicci PG: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11: 71-76, 2005. (Pubitemid 40215840)
48. Shen J, Huang C, Jiang L, Gao F, Wang Z, Zhang Y, Bai J, Zhou H and Chen Q: Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem Pharmacol 73: 1901-1909, 2007. (Pubitemid 46677907)
49. Rikiishi H, Shinohara F, Sato T, Sato Y, Suzuki M and Echigo S: Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int J Oncol 30: 1181-1188, 2007.
50. Suzuki M, Endo M, Shinohara F, Echigo S and Rikiishi H: Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells. Cancer Chemother Pharmacol 64: 1115-1122, 2009.
51. Jin KL, Park JY, Noh EJ, Hoe KL, Lee JH, Kim JH and Nam JH: The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells. J Gynecol Oncol 21: 262-268, 2010.